Abstract 100P
Background
Cardiac hemangiosarcomas originate from blood vessel-forming cells and are described as aggressive malignant tumors. However, with limited data on the safety and efficacy of different therapeutic modalities an optimal treatment strategy remains unclear. We conducted a comprehensive analysis on the effect of various therapeutic procedures on the survival outcomes of cardiac hemangiosarcoma patients.
Methods
In a retrospective cohort analysis, we examined data from 196 patients diagnosed with cardiac hemangiosarcoma between 2000 to 2020, sourced from the SEER database. Cox proportional hazards model assessed the relationships between these factors and survival outcomes.
Results
The study included 196 patients (47.7 females) with cardiac hemangiosarcoma. Among the subjects, 55.6% were less than 50 years old, while 44.4% were aged 50 or older. The grade distribution was as follows: 2.6% for Grade 2, 18.9% for Grade 3, 19.9% for Grade 4, while 58.7% were of unknown grade. Most patients were in distant stage, 41.3%. Treatment modalities among the participants were diverse: 53.6% underwent surgery, 20.4% received radiation therapy, and 61.7% were treated with chemotherapy. By the study's conclusion, 89.3% of the patients had deceased, while 10.7% were still living. Tumor size distribution revealed 4.6% with a size less than 3cm, 38.8% with a size equal to or greater than 3cm, and 56.6% with unknown tumor size. Univariate and multivariate analyses using a Cox Proportional Hazard Model demonstrated significant associations with survival outcomes for surgery (HR=0.614, 95% CI [0.454-0.831], P=0.002; HR=0.562, 95% CI [0.414-0.764], P=<0.001), chemotherapy (HR=0.529, 95% CI [0.386-0.725], P=<0.001; HR=0.49, 95% CI [0.356-0.676], =P=<0.001), and in significant in radiation (HR=0.786, 95% CI [0.545-1.132], P=0.196; HR=0.754, 95% CI [0.523-1.089], P=0.132).
Conclusions
Our findings revealed that surgery and chemotherapy were significantly associated with improved overall survival, while radiation therapy had no significant effect on patients with cardiac hemangiosarcoma. The results require further validation by future prospective studies and exploration in the optimal sequence each therapeutic modality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.